Background
Methods
Patient and controls
ProtoArray® screening
Expression and purification of the DIDO1 protein
Western blotting
Epitope prediction and peptide synthesis
-
bCPSF3-165: biotin-FMIEIAGVKLLYTGD
-
bCPSF3-298: biotin-NINNPFVFKHISNLK
-
bCPSF3-545: biotin-KPALKVFKNITVIQE
-
bCPSF2-607: biotin-QVRLKDSLVSSLQFC
-
bCPSF2-712: biotin-QSVFMNEPRLSDFKQ
-
bFOXJ2-426: biotin-KMVNRLNWSSIEQSQ
Peptide array method
Peptide synthesis
-
bFOXJ2-426: biotin-KMVNRLNWSSIEQSQ (94.9%)
-
bCPSF2-607: biotin-QVRLKDSLVSSLQFC (99.2%)
-
bDIDO1-297: biotin-AMAASKKTAPPGSAVGKQ (98.4%)
Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA)
Immunohistochemical staining
Nested case–control study
Statistical analysis
Results
Recognition of DIDO1, CPSF2, and FOXJ2 via serum igg antibodies of patients with atherosclerosis
Abbreviated name | Accession number | Full name | Screening method | Reference |
---|---|---|---|---|
DIDO1 | BC000770.1 | Death inducer obliterator-1 | Protein array | This report |
CPSF2 | NM_017437.1 | Cleavage and polyadenylation specific factor 2, 100 kDa | Protein array | This report |
FOXJ2 | NM_018416.2 | Forkhead box J2 | Protein array | This report |
ACTR3B | NM_020445.6 | ARP3 actin-related protein 3 homolog B | SEREX | [40] |
ADAMTS7 | NM_014272.3 | ADAM metallopeptidase with thrombospondin type 1 motif, 7 | SEREX | |
AR141352 | NM_133494 | NIMA (never in mitosis gene a)-related kinase 7 | SEREX | |
ASXL2 | NM_018263.6 | Additional sex combs-like 2 | SEREX | [43] |
ATP2B4 | NM_001001396.2 | ATPase, Ca++ transporting, plasma membrane 4 | Protein array | [54] |
BAZ1B | NM_032408 | Bromodomain adjacent to zinc finger domain, 1B | SEREX | |
BMP1 | NM_006129.4 | Bone morphogenetic protein 1 | SEREX | |
CBX1 | NM_001127228 | Chromobox homolog 1 | SEREX | [41] |
CBX5 | NM_012117 | Chromobox homolog 5 | SEREX | [41] |
CCNG2 | NM_004354.3 | Cyclin G2 | Protein array | [48] |
CEP290 | NM_014684 | Centrosomal protein 290 kDa | SEREX | |
CLDND1 | NM_001040181 | Claudin domain containing 1 | Protein array | [48] |
COPE | CR456886 | Coatomer protein complex subunit epsilon | SEREX | [36] |
CRIM1 | NM_016441.2 | Cysteine-rich transmembrane BMP regulator 1 (chordin-like) | SEREX | |
CTNNA1 | NM_001903.5 | Catenin alpha 1 | SEREX | [40] |
CTNND1 | NM_001085458 | Catenin delta 1 | Protein array | [48] |
DEF8 | NM_207514 | Differentially expressed in FDCP 8 homolog (mouse) | SEREX | |
DHPS | NM_001930 | Deoxyhypusine synthase | Protein array | [55] |
DNAJA1 | NM_001539 | DnaJ heat shock protein family (Hsp40) member A1 | SEREX | [42] |
DNAJC2 | NM_014377 | DnaJ heat shock protein family (Hsp40) member C2 | SEREX | [42] |
DST | NM_015548 | Dystonin | SEREX | |
EEF1A1 | NM_001402.5 | Eukaryotic translation Elongation factor 1 alpha 1 | SEREX | [56] |
EEF1G | NM_001404.4 | Eukaryotic translation elongation factor 1 gamma | SEREX | |
EIF2A | NM_032025.3 | Eukaryotic translation initiation factor 2A, 65 kDa | SEREX | |
FER1L3 | NM_133337 | Myoferlin | SEREX | |
GOPC | NM_001017408 | Golgi associated PDZ and coiled-coil motif containing | SEREX | |
H3F3B | NM_005324 | H3 histone, family 3B | SEREX | |
HM13 | AF483215 | Histocompatibility (minor) 13 | SEREX | |
HSPA8 | NM_006597 | Heat shock 70 kDa protein 8 | SEREX | |
HSPB1 | NM_001540.3 | Heat shock 27 kDa protein 1 | SEREX | |
KIAA0020 | NM_014878 | KIAA0020 | SEREX | [56] |
LGALS9 | NM_009587 | Galectin 9 | SEREX | [39] |
LRPAP1 | NM_002337 | Low-density lipolipoprotein receptor–related protein–associated protein 1 | SEREX | [57] |
MAGT1 | NM_032121.5 | Magnesium transporter 1 | SEREX | |
MMP1 | NM_002421 | Metalloproteinase 1 | SEREX | [41] |
MYBBP1A | NM_001105538 | MYB binding protein 1a | Protein array | [48] |
NAV2 | NM_145117.4 | Neuron navigator 2 | SEREX | |
PARC | NM_015089 | p53-associated parkin-like cytoplasmic protein | SEREX | |
PDCD11 | NM_014976.2 | Programmed cell death 11 | SEREX | |
PFKFB3 | NM_004566 | 6-Phosphofructo-2-kinase/Fructose-2,6-biphosphatase 3 | SEREX | |
PHF20 | NM_016436 | PHD finger protein 20 | SEREX | |
PPP1R15A | NM_014330 | Protein phosphatase 1 regulatory subunit 15A | SEREX | |
PRCP | NM_005040.1 | Prolylcarboxypeptidase | Protein array | [60] |
PSAP | NM_002778 | Prosaposin | SEREX | |
RANBP2L1 | NM_005054 | RAN binding protein 2-like 1 | SEREX | |
RBCK1 | NM_031229 | RanBP-type and C3HC4-type zinc finger containing 1 | SEREX | |
RBPJ | NM_005349 | Recombination signal binding protein for immunoglobulin kappa J region | SEREX | |
ROCK1 | NM_005406 | Rho-associated, coiled-coil containing protein kinase 1 | SEREX | |
RPA1 | NM_002945 | Replication protein A1 | SEREX | |
RPA2 | NM_002946 | Replication protein A2 | SEREX | [39] |
RPL3 R | NM_000967 | Ribosomal protein L3t | SEREX | |
SC65 | BC007942 | Synaptonemal complex protein SC65 | SEREX | [39] |
SH3BP5 | NM_004844 | SH3 domain-binding protein 5 | Protein array | [51] |
SMARCA4 | NM_001128847 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 | SEREX | |
SNX16 | NM_022133.4 | Sorting Nexins 16 | SEREX | [37] |
SOSTDC1 | NM_015464 | Sclerostin domain containing 1 | Protein array | [48] |
SPARC | NM_003118 | Secreted protein acidic and cysteine-rich | SEREX | |
SPOCK1 | NM_004598 | SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1 | SEREX | [56] |
TBC1D2 | NM_001267571 | TBC1 domain family, member 2 | SEREX | |
TBC1D4 | NM_014832 | TBC1 domain family, member 4 | SEREX | |
TEX261 | NM_144582 | Testis expressed 261 | SEREX | |
TFAM | NM_003201 | Transcription factor A, mitochondrial | Protein array | [48] |
THBS1 | NM_003246 | Thrombospondin 1 | SEREX | |
TMEFF1 | NM_003692 | Transmembrane protein with EGF-like and two follistatin-like domains 1 | SEREX | |
TOP3B | NM_003935 | DNA topoisomerase III beta | Protein array | [48] |
TUBB2C | NM_006088 | Tubulin, beta 2C | SEREX | [56] |
TYMS | NM_001071 | Thymidylate synthetase | SEREX | |
WDR36 | NM_139281.2 | T cell activation WD repeat protein | SEREX | [39] |
XPO1 | NM_003400.3 | Exportin 1 | SEREX | |
XRCC4 | NM_022406 | X-ray repair cross complementing 4 | SEREX | |
ZFP36L1 | NM_004926 | ZFP36 ring finger protein like 1 | SEREX |
Presence of serum antibodies against purified proteins in patients with TIA or AIS
Elevation of serum DIDO1-Ab, FOXJ2-Ab, and CPSF2-Ab levels in patients with TIA or AIS
Sample information | HD | TIA | AIS | |
Total sample number | 285 | 92 | 464 | |
Male/female | 188/97 | 55/37 | 271/193 | |
Age (average ± SD) | 52.3 ± 11.7 | 70.2 ± 11.6 | 75.5 ± 11.5 | |
Alpha analysis (antibody level) | DIDO1-Ab | FOXJ2-Ab | CPSF2-Ab | |
HD | Average | 4736 | 8568 | 2515 |
SD | 3179 | 5103 | 1061 | |
Cutoff value | 11,095 | 18,774 | 4638 | |
Positive no. | 19 | 16 | 12 | |
Positive (%) | 6.7% | 5.6% | 4.2% | |
TIA | Average | 6950 | 12,390 | 3792 |
SD | 5251 | 7533 | 4280 | |
Positive no. | 14 | 13 | 15 | |
Positive (%) | 15.2% | 14.1% | 16.3% | |
P (TIA vs HD) | 0.0002 | < 0.0001 | 0.0056 | |
AIS | Average | 7309 | 13,255 | 3291 |
SD | 5415 | 8042 | 2396 | |
Positive no. | 81 | 91 | 69 | |
Positive (%) | 17.5% | 19.6% | 14.9% | |
P (AIS vs HD) | < 0.0001 | < 0.0001 | < 0.0001 |
Elevation of serum DIDO1, FOXJ2, and CPSF2 antibody levels in patients with AMI or DM
Alpha analysis (antibody level) | DIDO1-Ab | FOXJ2-Ab | CPSF2-Ab | |
---|---|---|---|---|
HD | Average | 11,373 | 12,218 | 5571 |
SD | 1939 | 6636 | 2390 | |
Cutoff value | 15,251 | 25,490 | 10,351 | |
Positive no. | 4 | 4 | 7 | |
Positive (%) | 3.1% | 3.1% | 5.5% | |
AMI | Average | 11,634 | 22,965 | 5343 |
SD | 2405 | 16,329 | 3070 | |
Positive no. | 10 | 44 | 6 | |
Positive (%) | 7.8% | 34.4% | 4.7% | |
P (AMI vs HD) | 0.342 | < 0.0001 | 0.508 | |
DM | Average | 11,199 | 21,718 | 7232 |
SD | 2252 | 24,383 | 3798 | |
Positive no. | 7 | 29 | 17 | |
Positive (%) | 5.5% | 22.7% | 13.3% | |
P (DM vs HD) | 0.508 | < 0.0001 | < 0.0001 |
Elevation of serum DIDO1, FOXJ2, and CPSF2 antibody levels in patients with CKD
Sample information | HD | Type-1 CKD | Type-2 CKD | Type-3 CKD | |
Total sample number | 82 | 145 | 32 | 123 | |
Male/female | 44/38 | 106/39 | 21/11 | 70/53 | |
Age (average ± SD) | 44.1 ± 11.2 | 66.0 ± 10.4 | 76.0 ± 9.8 | 62.0 ± 11.7 | |
Alpha analysis (antibody level) | DIDO1-Ab | FOXJ2-Ab | CPSF2-Ab | ||
HD | Average | 3166 | 1300 | 914 | |
SD | 1423 | 517 | 298 | ||
Cutoff value | 6012 | 2334 | 1509 | ||
Positive no. | 6 | 3 | 3 | ||
Positive rate (%) | 7.3% | 3.7% | 3.7% | ||
Type 1-CKD | Average | 6805 | 2141 | 939 | |
SD | 4675 | 1330 | 382 | ||
Positive no. | 63 | 41 | 7 | ||
Positive rate (%) | 43.4% | 28.3% | 4.8% | ||
P (vs HD) | < 0.0001 | < 0.0001 | 0.579 | ||
Type 2-CKD | Average | 6693 | 2245 | 1020 | |
SD | 3347 | 930 | 281 | ||
Positive no. | 12 | 11 | 2 | ||
Positive rate (%) | 37.5% | 34.4% | 6.3% | ||
P (vs HD) | < 0.0001 | < 0.0001 | 0.081 | ||
Type 3-CKD | Average | 5264 | 1770 | 936 | |
SD | 2161 | 829 | 421 | ||
Positive no. | 33 | 17 | 10 | ||
Positive rate (%) | 26.8% | 13.8% | 8.1% | ||
P (vs HD) | < 0.0001 | < 0.0001 | 0.656 |
ROC analysis
DIDO1-Ab vs TIA | DIDO1-Ab vs AIS | |||
AUC | 0.6767 | 0.6023 | ||
95% CI | 0.6001–0.7533 | 0.5367–0.6680 | ||
Cutoff value | 14,184 | 19,924 | ||
Sensitivity (%) | 77.9% | 27.9% | ||
Specificity (%) | 49.6% | 91.9% | ||
P value | < 0.0001 | 0.0033 | ||
DIDO1-Ab vs AMI | DIDO1-Ab vs DM | |||
AUC | 0.5163 | 0.5347 | ||
95% CI | 0.4454–0.5875 | 0.4638–0.6057 | ||
Cutoff value | 13,519 | 10,700 | ||
Sensitivity (%) | 22.7% | 46.9% | ||
Specificity (%) | 85.8% | 63.8% | ||
P value | 0.650 | 0.338 | ||
DIDO1-Ab vs type 1 CKD | DIDO1-Ab vs type 2 CKD | DIDO1-Ab vs type 3 CKD | ||
AUC | 0.8665 | 0.8728 | 0.8227 | |
95% CI | 0.8144 to 0.9186 | 0.8092 to 0.9364 | 0.7611 to 0.8843 | |
Cutoff value | 3375 | 3511 | 3158 | |
Sensitivity (%) | 93.1% | 90.6% | 91.9% | |
Specificity (%) | 69.1% | 70.2% | 63.1% | |
P value | < 0.0001 | < 0.0001 | < 0.0001 | |
DIDO1pep-Ab vs TIA | DIDO1pep-Ab vs AIS | |||
AUC | 0.6503 | 0.6611 | ||
95% CI | 0.5751–0.7256 | 0.6138–0.7084 | ||
Cutoff value | 4662 | 8413 | ||
Sensitivity (%) | 87.9% | 43.9% | ||
Specificity (%) | 38.3% | 81.9% | ||
P value | 0.0003 | < 0.0001 | ||
FOXJ2-Ab vs TIA | FOXJ2-Ab vs AIS | CPSF2-Ab vs TIA | CPSF2-Ab vs AIS | |
AUC | 0.6696 | 0.7006 | 0.6314 | 0.6369 |
95% CI | 0.6066 to 0.7326 | 0.6626 to 0.7386 | 0.5631–0.6997 | 0.5970–0.6768 |
Cutoff value | 8978 | 8920 | 2643 | 2644 |
Sensitivity (%) | 60.9% | 65.1% | 54.4% | 57.8% |
Specificity (%) | 66.0% | 66.0% | 67.7% | 67.7% |
P value | < 0.0001 | < 0.0001 | 0.0002 | < 0.0001 |
FOXJ2-Ab vs AMI | FOXJ2-Ab vs DM | CPSF2-Ab vs AMI | CPSF2-Ab vs DM | |
AUC | 0.7418 | 0.6584 | 0.5522 | 0.6464 |
95% CI | 0.6813 to 0.8022 | 0.5922 to 0.7245 | 0.4817 to 0.6226 | 0.5792 to 0.7136 |
Cutoff value | 14,437 | 20,978 | 5356 | 6145 |
Sensitivity (%) | 68.0% | 34.4% | 63.3% | 55.5% |
Specificity (%) | 71.1% | 91.4% | 49.2% | 70.3% |
P value | < 0.0001 | < 0.0001 | 0.149 | < 0.0001 |
FOXJ2-Ab vs type 1 CKD | FOXJ2-Ab vs type 2 CKD | FOXJ2-Ab vs type 3 CKD | ||
AUC | 0.7812 | 0.8769 | 0.7151 | |
95% CI | 0.7200 to 0.8424 | 0.8124 to 0.9413 | 0.6439 to 0.7862 | |
Cutoff value | 1236 | 1391 | 1354 | |
Sensitivity (%) | 83.5% | 93.8% | 69.9% | |
Specificity (%) | 59.5% | 71.4% | 69.1% | |
P value | < 0.0001 | < 0.0001 | < 0.0001 | |
CPSF2-Ab vs Type-1 CKD | CPSF2-Ab vsType-2 CKD | CPSF2-Ab vsType-3 CKD | ||
AUC | 0.5040 | 0.6387 | 0.5196 | |
95% CI | 0.4262–0.5817 | 0.5274–0.7500 | 0.4395–0.5996 | |
Cutoff value | 641.5 | 901 | 706 | |
Sensitivity (%) | 11.7% | 65.6% | 29.3% | |
Specificity (%) | 93.9% | 62.2% | 80.5% | |
P value | 0.921 | 0.022 | 0.635 |
Serum DIDO1-Ab, FOXJ2-Ab, and CPSF2-Ab levels in cancer
Association of serum DIDO1-Ab, FOXJ2-Ab, and CPSF2-Ab levels with autoimmune diseases
Association of serum DIDO1-Ab, FOXJ2-Ab, and CPSF2-Ab levels with pulmonary diseases
Correlation analysis
Present disease | HD | DSWMH | asympt-CI | TIA | AIS | cCI | |
Sample number | 188 | 162 | 18 | 66 | 351 | 66 | |
DIDO1pep-Ab level | Average | 3381 | 3523 | 3481 | 4443 | 4688 | 4347 |
SD | 1660 | 1750 | 2099 | 2576 | 2740 | 3017 | |
P value (vs HD) | – | ns | ns | < 0.01 | < 0.001 | < 0.05 | |
FOXJ2-Ab level | Average | 4627 | 4995 | 4902 | 5794 | 6298 | 7022 |
SD | 1972 | 2232 | 1854 | 2368 | 3308 | 5646 | |
P value (vs HD) | – | ns | ns | < 0.01 | < 0.001 | < 0.001 | |
CPSF2-Ab level | Average | 7322 | 7571 | 8312 | 11,778 | 8722 | 10,088 |
SD | 3415 | 2942 | 2461 | 16,843 | 3970 | 4240 | |
P value (vs HD) | – | ns | < 0.05 | < 0.01 | < 0.001 | < 0.001 | |
Sex | Male | Female | |||||
Sample number | 528 | 389 | |||||
DIDO1pep-Ab level | Average | 4081 | 4038 | ||||
SD | 2493 | 2244 | |||||
P value (vs Male) | 0.781 | ||||||
FOXJ2-Ab level | Average | 5772 | 5443 | ||||
SD | 3077 | 3084 | |||||
P value (vs male) | 0.111 | ||||||
CPSF2-Ab level | Average | 8633 | 8420 | ||||
SD | 5493 | 6553 | |||||
P value (vs male) | 0.155 | ||||||
Complication | DM− | DM+ | |||||
Sample number | 732 | 180 | |||||
DIDO1pep-Ab level | Average | 4059 | 4047 | ||||
SD | 2469 | 2027 | |||||
P value (vs DM−) | 0.949 | ||||||
FOXJ2-Ab level | Average | 5589 | 5763 | ||||
SD | 3104 | 2987 | |||||
P value (vs DM−) | 0.488 | ||||||
CPSF2-Ab level | Average | 8319 | 9437 | ||||
SD | 5373 | 7822 | |||||
P value (vs DM−) | 0.015 | ||||||
Complication | HT− | HT+ | |||||
Sample number | 347 | 565 | |||||
DIDO1pep-Ab level | Average | 3830 | 4196 | ||||
SD | 2217 | 2477 | |||||
P value (vs HT−) | 0.021 | ||||||
FOXJ2-Ab level | Average | 5093 | 5948 | ||||
SD | 2373 | 3405 | |||||
P value (vs HT−) | < 0.0001 | ||||||
CPSF2-Ab level | Average | 7699 | 9065 | ||||
SD | 6095 | 5804 | |||||
P value (vs HT−) | < 0.0001 | ||||||
Complication | CVD− | CVD+ | |||||
Sample number | 861 | 51 | |||||
DIDO1pep-Ab level | Average | 4003 | 4966 | ||||
SD | 2360 | 2673 | |||||
P value (vs CVD−) | 0.015 | ||||||
FOXJ2-Ab level | Average | 5559 | 6712 | ||||
SD | 3050 | 3408 | |||||
P value (vs CVD−) | 0.022 | ||||||
CPSF2-Ab level | Average | 8499 | 9232 | ||||
SD | 6037 | 4239 | |||||
P value (vs CVD−) | 0.142 | ||||||
Complication | Lipidemia− | Lipidemia+ | |||||
Sample number | 649 | 263 | |||||
DIDO1pep-Ab level | Average | 4158 | 3806 | ||||
SD | 2497 | 2073 | |||||
P value (vs Lipidemia−) | 0.029 | ||||||
FOXJ2-Ab level | Average | 5702 | 5428 | ||||
SD | 3171 | 2841 | |||||
P value (vs Lipidemia−) | 0.203 | ||||||
CPSF2-Ab level | Average | 8146 | 9531 | ||||
SD | 3583 | 9534 | |||||
P value (vs Lipidemia−) | 0.145 | ||||||
Lifestyle | Non-smoker | Smoker | |||||
Sample number | 474 | 441 | |||||
DIDO1pep-Ab level | Average | 3732 | 4425 | ||||
SD | 2037 | 2676 | |||||
P value (vs non-smoker) | < 0.0001 | ||||||
FOXJ2-Ab level | Average | 5192 | 6111 | ||||
SD | 2793 | 3309 | |||||
P value (vs non-smoker) | < 0.0001 | ||||||
CPSF2-Ab level | Average | 8214 | 8901 | ||||
SD | 6086 | 5801 | |||||
P value (vs non-smoker) | 0.002 | ||||||
Lifestyle | Alcohol− | Alcohol+ | |||||
Sample number | 334 | 581 | |||||
DIDO1pep-Ab level | Average | 4001 | 4103 | ||||
SD | 2236 | 2476 | |||||
P value (vs Alcohol−) | 0.527 | ||||||
FOXJ2-Ab level | Average | 5691 | 5603 | ||||
SD | 3542 | 2793 | |||||
P value (vs Alcohol−) | 0.698 | ||||||
CPSF2-Ab level | Average | 8559 | 8591 | ||||
SD | 6946 | 5341 | |||||
P value (vs Alcohol−) | 0.361 |
Parameter* | Number of XY pairs | DIDO1pep-Ab | FOXJ2pep-Ab | CPSF2pep-Ab | |||
---|---|---|---|---|---|---|---|
r value** | P value | r value | P value | r value | P value | ||
Age | 851 | 0.2074 | < 0.0001*** | 0.2688 | < 0.0001 | 0.1657 | < 0.0001 |
Height | 844 | − 0.1227 | 0.0004 | − 0.1229 | 0.0003 | − 0.0799 | 0.0202 |
Weight | 848 | − 0.1047 | 0.0023 | − 0.1196 | 0.0005 | − 0.0707 | 0.0396 |
BMI | 843 | − 0.0311 | 0.3679 | − 0.0552 | 0.1098 | − 0.0343 | 0.3197 |
max IMT | 646 | 0.1908 | < 0.0001 | 0.2717 | < 0.0001 | 0.2161 | < 0.0001 |
A/G | 820 | − 0.0303 | 0.3858 | − 0.0484 | 0.1662 | − 0.0906 | 0.0094 |
AST | 848 | 0.0605 | 0.0782 | 0.0205 | 0.5523 | − 0.0496 | 0.1490 |
ALT | 847 | 0.0063 | 0.8545 | − 0.0079 | 0.8177 | − 0.0800 | 0.0199 |
ALP | 786 | 0.0850 | 0.0172 | 0.0743 | 0.0374 | 0.0319 | 0.3716 |
LDH | 822 | 0.0718 | 0.0395 | 0.0291 | 0.4046 | − 0.0134 | 0.7017 |
tBil | 830 | − 0.0576 | 0.0972 | − 0.0752 | 0.0304 | − 0.1024 | 0.0031 |
CHE | 646 | − 0.0895 | 0.0230 | − 0.1671 | < 0.0001 | − 0.0982 | 0.0125 |
γ-GTP | 795 | 0.0334 | 0.3474 | 0.0240 | 0.4996 | − 0.0028 | 0.9381 |
TP | 823 | − 0.0971 | 0.0053 | − 0.1443 | < 0.0001 | − 0.1084 | 0.0018 |
Albumin | 832 | − 0.0757 | 0.0289 | − 0.1294 | 0.0002 | − 0.1358 | < 0.0001 |
BUN | 846 | 0.0179 | 0.6038 | 0.0431 | 0.2103 | − 0.0381 | 0.2686 |
CRE | 842 | − 0.0090 | 0.7946 | 0.0472 | 0.1714 | − 0.0341 | 0.3233 |
eGFR | 758 | 0.0176 | 0.6284 | − 0.0255 | 0.4835 | 0.0230 | 0.5282 |
UA | 622 | 0.0336 | 0.4023 | 0.0255 | 0.5261 | 0.0050 | 0.9006 |
AMY | 527 | − 0.0780 | 0.0735 | − 0.0422 | 0.3350 | − 0.0391 | 0.3701 |
T-CHO | 744 | − 0.0520 | 0.1568 | − 0.0604 | 0.0994 | − 0.1207 | 0.0010 |
HDL-C | 550 | − 0.0458 | 0.2840 | − 0.0521 | 0.2222 | 0.0553 | 0.1952 |
TG | 589 | 0.0199 | 0.6303 | 0.0038 | 0.9274 | − 0.0405 | 0.3261 |
Na | 833 | 0.0200 | 0.5635 | 0.0233 | 0.5027 | 0.0005 | 0.9881 |
K | 832 | − 0.0275 | 0.4280 | − 0.0091 | 0.7928 | − 0.0072 | 0.8359 |
Cl | 833 | 0.0056 | 0.8708 | 0.0470 | 0.1752 | 0.0269 | 0.4376 |
Ca | 495 | − 0.0210 | 0.6408 | − 0.0815 | 0.0708 | − 0.0405 | 0.3682 |
IP | 388 | − 0.0023 | 0.9639 | − 0.0465 | 0.3618 | 0.0546 | 0.2836 |
Fe | 400 | − 0.0406 | 0.4185 | − 0.0575 | 0.2526 | − 0.0472 | 0.3465 |
CRP | 617 | 0.1172 | 0.0035 | 0.0775 | 0.0552 | 0.1041 | 0.0096 |
LDL-C | 440 | − 0.0513 | 0.2831 | − 0.0771 | 0.1071 | − 0.1180 | 0.0133 |
WBC | 846 | 0.1036 | 0.0026 | 0.0848 | 0.0138 | 0.0417 | 0.2262 |
RBC | 846 | − 0.0426 | 0.2155 | − 0.0649 | 0.0596 | − 0.0711 | 0.0386 |
HGB | 846 | − 0.0113 | 0.7420 | − 0.0329 | 0.3406 | − 0.0672 | 0.0508 |
HCT | 846 | − 0.0078 | 0.8214 | − 0.0271 | 0.4317 | − 0.0528 | 0.1249 |
MCV | 846 | 0.0683 | 0.0472 | 0.0959 | 0.0053 | 0.0510 | 0.1387 |
MCH | 846 | 0.0474 | 0.1681 | 0.0776 | 0.0242 | 0.0081 | 0.8136 |
MCHC | 846 | − 0.0149 | 0.6659 | − 0.0253 | 0.4635 | − 0.0617 | 0.0728 |
RDW | 846 | 0.0489 | 0.1551 | 0.0449 | 0.1928 | 0.0529 | 0.1245 |
PLT | 846 | − 0.0047 | 0.8919 | − 0.0443 | 0.1992 | 0.0128 | 0.7097 |
MPV | 846 | − 0.0201 | 0.5589 | − 0.0637 | 0.0646 | − 0.0012 | 0.9716 |
PCT | 846 | − 0.0030 | 0.9312 | − 0.0568 | 0.0993 | 0.0188 | 0.5853 |
PDW | 846 | − 0.0151 | 0.6611 | − 0.0587 | 0.0886 | − 0.0109 | 0.7512 |
BS | 783 | 0.0834 | 0.0195 | 0.0678 | 0.0581 | 0.0644 | 0.0718 |
HbA1c | 655 | − 0.0204 | 0.6031 | − 0.0170 | 0.6644 | − 0.0277 | 0.4789 |
Immunohistochemical analysis of antigenic proteins
JPHC cohort analysis
DIDO1-Ab vs AIS | DIDO1pep-Ab vs AIS | FOXJ2-Ab vs AIS | CPSF2-Ab vs AIS | ||
---|---|---|---|---|---|
2nd | Matched OR | 3.99 | 1.92 | 1.43 | 1.19 |
95% CI | 1.93–8.23 | 1.03–3.58 | 0.78–2.62 | 0.63–2.23 | |
3rd | Matched OR | 3.40 | 2.40 | 1.32 | 1.66 |
95% CI | 1.62–7.13 | 1.29–4.46 | 0.72–2.43 | 0.89–3.09 | |
Max | Matched OR | 4.02 | 2.66 | 2.24 | 2.41 |
95% CI | 1.94–8.35 | 1.43–4.95 | 1.27–3.95 | 1.33–4.37 |